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Cancer-specific binary expression 
system activated in mice by 
bacteriophage HK022 Integrase
Amer Elias1, Itay Spector1, Ilana Sogolovsky-Bard1, Natalia Gritsenko1, Lene Rask2,3, 
Yuli Mainbakh1, Yael Zilberstein1, Ezra Yagil1 & Mikhail Kolot1
Binary systems based on site-specific recombination have been used for tumor specific transcription 
targeting of suicide genes in animal models. In these binary systems a site specific recombinase or 
integrase that is expressed from a tumor specific promoter drives tumor specific expression of a 
cytotoxic gene. In the present study we developed a new cancer specific binary expression system 
activated by the Integrase (Int) of the lambdoid phage HK022. We demonstrate the validity of this 
system by the specific expression of a luciferase (luc) reporter in human embryonic kidney 293T 
(HEK293T) cells and in a lung cancer mouse model. Due to the absence viral vectors and of cytotoxicity 
the Int based binary system offers advantages over previously described counterparts and may 
therefore be developed into a safer cancer cell killing system.
Site-specific recombinases are widely used for genome manipulations by catalysis of site-specific recombination 
reactions (SSR) between two defined DNA sequences of ~20–200 base pairs (bp) functioning as recombination 
sites (RSs)1–6. SSR reactions result in integration, excision or inversion, depending on the location and relative ori-
entation of the RSs. A widely used SSR-based technique is the recombinase-mediated-cassette-exchange (RMCE) 
reaction allowing clean exchange of an existing gene by a gene of interest7. SSR systems that are currently used to 
manipulate genomes of higher organisms include those of the bacteriophage P1 Cre/lox, the baker yeast Flp/frt 
and the bacteriophage ϕ C31 Int/att. The recombinases of the former two systems belong to the tyrosine recom-
binase family and of the latter system to the serine recombinase family8.
SSR systems are also used in binary systems for cell and gene specific expression that are based on two DNA 
modules. One module carries a recombinase substrate comprising a target gene silenced by a transcription termi-
nator placed between two RSs. The second module carries the recombinase gene controlled by a cell type specific 
promoter. This promoter targets the expression of the SSR to the desired cells where it excises the terminator and 
thus activates the expression of the gene of interest9–11.
Coliphage HK022 encodes an Integrase recombinase (Int) belonging to the tyrosine integrase family that 
catalyzes the integration of the phage genome into its RS on the Escherichia coli chromosome as well as its exci-
sion from the E. coli chromosome. In these regards it acts very much like the well-documented coliphage λ 
Integrase12. Int targets a 21 bp long bacterial RS termed attB or BOB′ to indicate its composition of a central 
7 bp overlap region (O) and the two flanking incomplete inverted repeats of 7 bp (B and B′ ). O is the site of DNA 
exchange while B and B′ are Int binding sites. The phage recombination site termed attP is ~200 bp long. It con-
tains a 21 bp core (COC′ ) that is similar to attB and is flanked by two long arms (P and P′ ) that carry additional 
Int binding sites and others that bind accessory proteins required for the SSR reactions. The phage integration 
reaction occurs between attP and attB. It yields two hybrid recombination sites flanking the integrated prophage 
termed attL (BOP′ ) and attR (POB′ ). The reverse prophage excision reaction occurs between the attL and attR 
sites and restores the original attP and attB13. We have previously applied Int for genome manipulation in plants, 
cyanobacteria and human cells and have shown that the accessory proteins that are required in the E. coli host are 
dispensable in the eukaryotic milieu14–18. In the present study we developed a cancer specific binary cell expres-
sion system that is based on the hTERT promoter. hTERT serves as the catalytic reverse transcriptase subunit of 
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telomerase and is specifically expressed in immortal and cancer cells19,20. In this binary cell expression system 
hTERT-promoted Int specifically activates a luc reporter in immortalized human embryonic kidney 293 cells 
(HEK293T) and in mouse lung tumors originating from injected Lewis lung carcinoma line 1 (LLC1). This cancer 
specific expression system offers certain advantages over those previously described9–11 and may be applied to 
express toxins specifically in cancerous tumors.
Results
Cancer specific luc reporter expression mediated by an Int-based binary system. Two plas-
mids were constructed to generate a cancer specific binary cell expression system activated by Int. One plasmid 
expresses the int gene under the control of the cancer specific promoter hTERT19,20 or by the constitutive cyto-
megalovirus (CMV) promoter as control. The other carries a luc gene separated from a CMV promoter by a tran-
scription terminator (Stop) flanked by tandem attR and attL recombination sites (Fig. 1). Int-catalyzed attR x attL 
recombination excises Stop allowing expression of the luc reporter.
Validation that the luc reporter cancer specific binary cell expression system is activated by Int 
in HEK293T cells. Our first goal was to validate the efficiency of the binary cell expression system activated 
by Int in cancer cells. To this end we employed the immortalized HEK293T cells that are transformed both by 
adenovirus and by the SV40 large tumor antigen. This line expresses a high level of hTERT sufficient to main-
tain their telomeres indefinitely, unlike normal human cells that do not express hTERT21,22. Therefore, placing 
int under the control of hTERT promoter was expected to express in the HEK293T cells. HEK293T cells were 
co-transfected with the silent luc substrate carrying the CMV-attR-Stop-attL-luc cassette (pAE1855, Fig. 1) and 
a plasmid expressing int either under the control of the cancer specific hTERT promoter (pNA1263) or under 
the constitutive CMV promoter (pNA979) that served as a positive control. The quantitative analysis of the Luc 
activity assay in HEK293T cells (Fig. 2A) indicated that int driven by the hTERT promoter catalyzed attR x attL 
excision at ~20% the extent of that observed with the CMV control. In the absence of int Luc activity was negligi-
ble. Thus, int expressed from the cancer specific hTERT promoter catalyzed rather efficiently site-specific recom-
bination in the immortalized HEK293T cells.
A lung-specific DNA delivery in mice. Efficient in vivo transformation and gene delivery in mammals is a 
considerable technical challenge. Among different approaches and DNA delivery agents, including lentiviral vec-
tors, we have observed that the linear in vivo-jet PEI (Polyplus, France) is the most effective. This linear polyeth-
ylenimine reagent is used to deliver DNA, siRNA and oligonucleotides. It forms stable complexes with the nucleic 
acid cargo, protecting it from degradation thereby facilitating in vivo delivery. These complexes pass the capillary 
barrier in the lung, explaining the propensity of in vivo-jet PEI to deliver its cargo specifically into lungs23. As 
reporter, we found that the Luciferase gene (luc), whose product emits characteristic yellow-green biolumines-
cence in the presence of its luciferin substrate is most suitable. BALB/c mice were intravenous (IV) tail-injected 
with a sample of the jet PEI delivery agent complexed with a reporter plasmid (pYM1600) that carries the luc gene 
under the control of CMV promoter. 24 hours later the mice were injected with the Luciferase substrate luciferin 
and underwent bioluminescence imaging. The treated mouse (Fig. 3A) was compared with a luciferin-injected 
luc-transgenic mouse as a positive control (Fig. 3B) and a BALB/c mouse injected with the luciferin substrate 
alone as a negative control (Fig. 3C). The treated mouse injected with the gene delivery system (Fig. 3A) showed 
specific bioluminescent activity in the lung area while the transgenic mouse (Fig. 3B) showed abdominal activity. 
Figure 1. Scheme of the Int-catalyzed binary system to express a luc-reporter in cancer cells. (A) The 
recombination substrate carrying a silenced luc reporter separated from its CMV promoter by a transcription 
terminator (Stop) flanked by attR and attL recombination substrates. (B) The recombination products generated 
by Int: The activated luc-reporter separated from its CMV promoter by the small bacterial recombination site 
attB (top), and the excised non-replicative Stop (bottom).
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We concluded that the in vivo-jet PEI carried the luc plasmid to the lungs and therefore we set out to develop lung 
cancer mice as an in vivo model to explore our Int activated cancer specific binary system in vivo.
Int activates the luc reporter binary system in the lungs of BALB/c mice. We next tested if our 
binary system is also active in vivo in mice as it does in cell culture. Two mice were IV-tail injected with jet PEI 
complexed with different doses of the constitutive CMV-int expressing plasmid, and the silent attR-Stop-attL-luc 
substrate plasmid (20 μ g + 30 μ g and 10 μ g + 40 μ g respectively). As a positive control two mice were each sim-
ilarly treated with two doses of a CMV-luc expressing plasmid (pYM1600, 50 μ g and 10 μ g). 24 hours later bio-
luminescence imaging of these mice (Fig. 4A) has shown that in mouse No. 4 injected with the higher dose of 
the silent substrate along with the lower dose of the Int expressing plasmid Int has catalyzed the recombination 
reaction that lead to the activation of the silent luc reporter in the lungs’ area (Fig. 1). Quantification of these 
assays (Fig. 4B) shows that the efficiency of the binary reaction is comparable to that acquired by control mouse 
No. 2 injected with higher dose of a CMV-luc expressing plasmid. These results show that under a constitutive 
Figure 2. Luc activity assays of the hTERT-promoted Int-activation of the binary system in HEK293T cells 
(A) and in LLC-Kat cells (B), each compared with that of a CMV-promoted Int system. The data represent the 
mean value of three experiments; the error bars indicate standard deviation. RSL represents the attR-Stop-attL 
cassette (Fig. 1A).
Figure 3. (A) Delivery of a CMV-luc-carrying plasmid (pYM1600) complexed with the in vivo-jet PEI into the 
lungs of an IV tail-injected BALB/c mouse. (B) Luc activity in a BALB/c luc-transgenic mouse. (C) Non-injected 
BALB/c mouse treated with luciferin.
www.nature.com/scientificreports/
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CMV-int expression the binary system is also active in vivo in the mouse lungs. The sensitivity of Luc detection 
strongly depends on the concentration ratios of the injected plasmid, explained by the virtual absence of a positive 
signal in mice Nos 1 and 3.
An experimental lung cancer mice model. Having demonstrated that the jet PEI DNA delivery reagent 
has delivered the luc plasmid exclusively to the lungs, our next step was to develop a mouse lung cancer model. 
To this end we used the Lewis lung carcinoma line 1 (LLC1)24 labelled with a far-red mutant of the red fluorescent 
gene of the sea anemone Entacmaea quadricolor known as Katushka cells (LLC-Kat)25,26. LLC1 cells remain highly 
tumorigenic in C57BL/6 mice and produce primary tumors and lung metastases. LLC1 cells are widely used as 
a model for the development of lung-metastatic tumors in mice and are useful in studying the mechanisms of 
cancer chemotherapeutic agents27. The presence of the Katushka label in LLC1 cells facilitates the detection of the 
lung metastases. A preliminary experiment with these cells shows that the binary system in these cells works as 
efficiently as in HEK293T cells (Fig. 2B).
Lung tumor metastases development was examined nine days following the injection of the LLC-Kat cells 
using in vivo micro-CT scanning. No tumors were detected in the lungs of the non-injected control [Fig. 5A(a)] 
whereas in the injected mice metastases were detected and localized in the lungs [arrows in Fig. 5B(a)]. The pres-
ence of metastases in LLC-Kat lungs were verified by ex-vivo fluorescence detection using the Maestro imaging 
system [Fig. 5B(b)] as compared to non-injected control [Fig. 5A(b). Further validation that the injected mice 
have acquired lung cancer were performed by H&E staining [Fig. 5B(c)] and by immunostaining using prolifer-
ating cancer nuclear antigen (PCNA) [Fig. 5B(d)] compared to control healthy lungs [Fig. 5A(c,d)]. In both cases 
the cancer metastases were evident. These data demonstrate the generation of a mouse lung cancer model using 
injection of LLC-Kat cells in C57BL/6 mice. Moreover the mice died after approximately 14 days post injections.
Cancer specificity of the Int-based binary cell expression system in mice. Finally, to test the can-
cer specificity of the binary Int-activated cell expression system in mice we performed a comparative analysis of 
this system between healthy C57BL/6 mice (Fig. 6A) and LLC-Kat-infected mice (Fig. 6B). In each of these two 
types of C57BL/6 mice, there were four groups (4 mice/group) that were IV tail-injected with the in vivo-jet PEI 
carrier complexed with different combinations of plasmids [panels (b–e)] while groups (a) remained untreated. 
In groups (b) the jet PEI carrier was complexed with the CMV-luc reported as positive control; in groups (c) the 
carrier was complexed with the silent recombination substrate (CMV-RSL-luc) alone to validate the absence of 
luc leakage; in groups (d,e) the carrier was complexed with the silenced substrate and the CMV-promoted Int 
(d) or with the hTERT-promoted Int (e). 24 hours later all mice were injected with luciferin and underwent bio-
luminescence imaging. As expected, in both healthy and cancerous mice the negative controls (a) and the ones 
treated with the silent substrate (c) showed no bioluminescence while the positive controls (b) did. So did the two 
groups (d) treated with the silent substrate along with the constitutive CMV-Int. However, in groups (e) only the 
cancerous mice treated with the silent substrate along with the hTERT-Int showed bioluminescence [Fig. 6B(e)] 
while in the healthy mice [Fig. 6A(e)] no bioluminescence was evident. Quantitative data of the bioluminescence 
mice are shown in Fig. 6C. Though in the cancerous mice the bioluminescence that was specifically catalyzed by 
the activity of hTERT-Int was lower compared to the constitutive CMV-Int, it was consistent with the expected 
specificity of our binary cancer cell expression system. To reinforce this cancer specific effect, the treated healthy 
and cancer mice underwent an immunohistochemical analysis of Luc expression (Fig. 7). The expected nega-
tive controls [panels (a,c)] did not show any immune response, the positive treatments [panels (b,d)] showed 
an immune response in both types of mice, while among the mice treated with the hTERT-Int binary system 
Figure 4. Int activity in the lungs of BALB/c mice. (A) Bioluminescence analysis. BALB/c mice were  
IV-injected with the in vivo-jet PEI complexed with indicated amounts of a CMV-luc plasmid as control 
(mice Nos 1 and 2) or with the complexed binary system (Nos 3 and 4). (B) Quantitative analysis of the 
bioluminescence data in the lung areas. The bars show the mean value of three experiments; the error bars 
indicate standard deviation.
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[panels (e)] only the cancerous ones showed an immune response. These results unambiguously confirmed the 
cancer specificity of our binary system.
Int does not show a toxic effect. Cre is one of the most widely SSRs used in mammalian gene manipula-
tions, however, Cre-dependent cellular toxicity has been reported in eukaryotic cells and organisms some even 
under transient conditions. These include reduced cell growth, chromosome aberrations, brain development, 
cardiac fibrosis, heart failure, thymic atrophy and severe hematological toxicity28–32. To examine if, under the con-
ditions of the above treatments, Int has any toxic effect we performed a TUNEL assay33 on the lungs of the same 
treated and untreated mice, thereby evaluating the apoptotic effect of the binary system. As evident from Fig. 8A 
all healthy lungs showed only negligible or no levels of apoptosis while the cancer lungs (Fig. 8B) were apoptotic 
as expected in those types of cells34. However, neither the lungs of the healthy mice treated with Int [Fig. 8A(d,e)] 
showed any apoptosis nor did their parallel cancer lungs [Fig. 8B(d,e)] show any increase in apoptosis relative 
to the ones in the absence of Int [panels (a,b)]. Quantitative data of the TUNEL assay confirm these observation 
(Fig. 8C), concluding that under our experimental conditions the amounts of supplied Int had no toxic effect.
Discussion
In the present study a new cancer specific binary cell expression system was developed that is based on the 
cancer-specific hTERT promoter showing that when the expression of coliphage HK022 Int is promoted by 
hTERT it activates, by a site-specific recombination reaction, the expression of the luc reporter gene exclusively 
in lung cancer cells without affecting normal tissues. In previous two reports that employed the Cre/lox system in 
such binary systems one used an adenovirus vector as the gene delivery carrier10 and the other combined the two 
binary elements (recombinase and RS) by crossing two transgenic mice, each carrying one of them9. The advan-
tages of our system are that it is not involved with a risky mammalian viral DNA carrier, that it can be delivered 
transiently and that under the experimental conditions Int does not show any toxicity. However, to test if Int may 
have some toxic effect a more extensive study that uses dose calibration and more than one toxicity assay are still 
missing.
When using a toxin gene to be specifically expressed in cancer cells it is essential that in the binary system 
the recombinase, being an enzyme, be promoted by a weak and specific promoter and that the toxic gene of the 
substrate be completely blocked by a tight transcription terminator. Because more substrate than enzyme needs 
to be delivered (Fig. 4A) the direct use of an hTERT promoted substrate, though being cancer specific, may be 
somewhat leaky on its voyage from its delivery spot to the cancer tissue thereby loosing specificity by damaging 
healthy tissues. Admittedly, a successful direct adenoviral carrier delivery of an hTERT promoted DTA toxin that 
cured ovary cancer in mice was reported35, nevertheless extra caution is always an advantage when it goes with 
cancer therapy.
With regards to possible off-target chromosomal integration events catalyzed by Int, we have previously 
shown that for Int to promote integration into secondary attB sites, such sites need to to carry a perfect wild type 
7 bp overlap with two flanking palindromic sequences18. Moreover, the attL and attR RS sites in the binary system 
Figure 5. In vivo imaging and immunohistochemistry analysis of lungs from healthy (A) and LLC-Kat injected 
C57BL/6 mice (B). Panels (a), in vivo imaging using a micro-CT device. Arrows mark metastases location; 
panels (b), ex vivo fluorescence imaging of the lungs using a Maestro system; panels (c), H&E staining; panels 
(d), immunostaining for PCNA.
www.nature.com/scientificreports/
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Figure 6. Cancer specificity of the binary hTERT-int based expression system using a cancerous mouse 
model. (A) Healthy C57BL/6 mice, (B) LLC-Kat injected counterparts. Panels (a), untreated mice; panels (b–e), 
IV-tail injected mice with the following plasmids complexed with the in vivo-jetPEI (b) CMV-luc, (pYM1600 - 50 μ g) 
(c) CMV-RSL-luc, (pAE1855 - 40 μ g) (d) CMV-RSL-luc, (pAE1855 - 40 μ g) + CMV-int, (pNA979 - 10 μ g) (e) 
CMV-RSL-luc, (pAE1855 - 40 μ g) + hTERT-int, (pNA1263 -10 μ g). The mice were injected 24 hr later with 
luciferin and their bioluminescence visualized as detailed in the Methods section. Each figure shows a typical 
mouse from a cohort of at least four mice. (C) Quantitative bioluminescence data. The bars show the mean value 
of four experiments; the error bars indicate standard deviation. RSL represents the attR-Stop-attL cassette.
Figure 7. Immunohistochemical analyses of Luc expression in the lungs of the healthy mice (A) and of the 
LLC-Kat injected mice (B). The mice were treated in the same order as in Fig. 6. Each figure shows a typical 
mouse from a cohort of at least four mice.
www.nature.com/scientificreports/
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are incomplete attPs. These and the fact that Int is weakly promoted by hTERT reduce the likelihood of off target 
Int-catalyzed integration events into human secondary attB sites.
In the Int-catalyzed binary system we employ the excisive attL and attR as recombination sites because they 
proved more efficient in mammalian recombination activity than does the attB + attP pair. Another reason is 
because their recombination leads to the short 21 bp attB site located between the promoter and the Luc gene 
(Fig. 1) that does not interfere with the expression of Int.
Preliminary experiments in cell culture with the binary system that carry subunit A of the diphtheria toxin 
(DTA) have already shown that with the DTA toxicity is clearly specific in the LLC-Kat as compared to normal 
human foreskin BJ cells and experiments with live mice using DTA and other toxins to eradicate the lung cancer 
are in progress. Success may render the system useful with other cancer cases using relevant cell specific promot-
ers and cell specific DNA carries.
Methods
Cells, growth conditions, mice, plasmids and oligomers. The bacterial host used was E. coli K12 
strain TAP114 (lacZ)M1536. It was grown and plated on Luria-Bertani (LB) rich medium with the appropriate 
antibiotics. Plasmid transformations were performed by electroporation37. Plasmids and oligomers are listed in 
Tables 1 and 2, respectively.
Human embryonic kidney cells HEK293T (ATCC CRL-3216) were cultured in Dulbecco’s modified Eagle’s 
medium. Mouse Lewis lung carcinoma LLC1 (ATCC CRL-1642) cells labelled by Katushka fluorescent gene 
reporter26 were cultured in RPMI medium.
For transient transfection of HEK293T and LLC-Kat, the cells (~6× 105) were plated in a 6 well plate and 
24 hours later treated with 2 μ g circular plasmid DNA using Puro-Fection transfection reagent (System 
Biosciences, USA) or TransIT-XT2 reagent (Mirus, Madison, WI, USA), respectively.
Figure 8. Immunohistochemical analysis of the TUNEL assays in the lungs of the healthy mice (A) and of 
the LLC-Kat injected mice (B) shown in the same order as in Fig. 6. Each figure shows a typical mouse from a 
cohort of at least four mice. (C) Quantitative data of the TUNEL assays in the lungs of the healthy mice (a) and 
of the LLC-Kat injected mice (b). The bars show the mean value of four experiments; the error bars indicate 
standard deviation.
www.nature.com/scientificreports/
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All mice procedures were performed in compliance with Tel Aviv University guidelines and protocols 
approved by the Institutional Animal Care and Use Committee. BALB/c and C57BL/6 strains were used for the 
mice experiments. In experiments involving injected LLC-Kat cells we used only the C57BL/6 strain.
All experiments described below were at least triplicated.
Plasmid construction. The pNA1263 plasmid (Table 1) carrying the int gene of HK022 under the control 
of hTERT promoter (hTERT) was constructed as follows. A BglII-HindIII hTERT PCR fragment, was gener-
ated using primers oEY638 + oEY639 (Table 2) and an hTERT-plasmid as template provided by Dr. S. C. Teng 
at the Department of Microbiology, National Taiwan University., and this PCR product was ligated into the 
matching sites of plasmid pNA97938. The pYM1600 plasmid, carrying the luc gene under the control of CMV 
promoter was constructed by the RF cloning procedure39. The CMV fragment that was obtained by PCR using 
plasmid pCDNA3 as a template and primers oEY843 + 850 was introduced into the luciferase reporter vec-
tor pGL2 vector (Promega, Madison, WI, USA). The pAE1855 plasmid, used as a substrate for the CMV-Luc 
assays, was constructed by ligation of a AgeI-NotI luc PCR fragment, obtained using pYM1600 as template 
and primers oEY807 + 808, into the same sites of the intermediate plasmid construct pAE1855inter carrying 
CMV- attR-Stop-attL cassette on pCDNA3. All plasmid constructs were verified by DNA sequencing.
Luc activity assay in cell culture. HEK293T or LLC-Kat cells transfected by the appropriate luc plasmids 
were collected 48 hours later by trypsin treatment and centrifugation, resuspension in 100 μ l of x1 Passive Lysis 
Buffer (Promega, Madison, WI, USA) followed by sonication and centrifugation. Quantitative Luc analysis of the 
supernatant was performed using Dual-luciferase reporter assay kit (Promega, Madison, WI, USA) and Synergy2 
plate reader (Biotek, USA) according to the manufacturer’s instructions.
DNA delivery and Luc activity imaging in mice. BALB/c or C57BL/6 mice were IV tail-injected with 
250 μ l of the in vivo-jet PEI delivery reagent (Polyplus transfection, France) complexed with an appropriate luc 
reporter plasmid. 24 hours later the mice were injected with 250 μ l of 3 mg/ml luciferin solution (Gold Biotechnology, 
USA) and underwent bioluminescence imaging by Biospace Photon Imager (Biospace Lab, France).
Lung cancer development and fluorescence imaging in mice. 0.8 × 106 LLC-Kat cells were IV 
tail-injected into 8 week old (17–21 gr) female C57BL/6 mice. Lung tumor metastases development was exam-
ined nine and twelve days following the injection using in vivo micro-CT scanner (TomoScope® In-vivo CT, 
Germany). The Katushka fluorescent signal in the lung metastases was analyzed on day 12 by an in vivo fluores-
cence imaging system (CRi MaestroTM, USA).
Preparation of Sections, Immunohistochemistry, Confocal Microscopy, apoptosis TUNEL assay 
and Image analysis. At the end of the experiments, biopsy specimens from lungs were collected, fixed in 
4% paraformaldehyde (PFA), embedded in paraplast and 5 μ m sections were prepared. Healthy and cancer lungs 
carrying metastases were treated in parallel with H&E stained and immune-stained anti-Luciferase antibody 
(Abcam, Cambridge, UK) at 1:100 dilution, with a PCNA kit (Life Technologies, Carlsbad, CA, USA) and with a 
TUNEL kit (MBL international, Woburn, MA, USA) according to manufacturer’s instructions. Donkey anti-Goat 
IgG (H + L) secondary antibodies conjugated with Alexa Fluor 488 dye (Life Technologies, Carlsbad, CA, USA) 
were used for Luciferase detection. Nuclei were detected with DAPI (Biolegend, San Diego, CA, USA). At least 20 
Plasmid Relevant genotype* Source
pNA979 CMV-int 38
pNA1263 hTERT-int this work
pYM1600 CMV-luc this work
pAE1855inter CMV-attR-Stop-attL this work
pAE1855 CMV-attR-Stop-attL-luc this work
pcDNA3 NeoR ApR Invitrogen
pGL2 luc ApR Promega
Table 1.  List of plasmids.
Primer Sequence Locus*
oEY638 GGAGATCTGGATTCGCGGGCACAGAC hTERT
oEY639 CCAAGCTTCCAGGGCTTCCCACGTG hTERT
oEY807 GGACCGGTATGGAAGACGCCAAAAACATAAAGAAAGGC luc
oEY808 GGGCGGCCGCTTACAATTTGGACTTTCCGCCCTTCTTGG luc
oEY843 GCTAACATAACCCGGGAGGTACCGAGCTCTCTGTGGATAACCGTATTACCGCCATGC CMV
oEY850 CAACAGTACCGGAATGCCAAGCTTACTTAGGCGCTAGCGGATCTGACGG CMV
Table 2.  List of oligomers.
www.nature.com/scientificreports/
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images of five tissue sections from 3 different mice per group were obtained for each analysis. Microscopic obser-
vation and image acquisition were performed using a Zeiss 510 Meta – NLO confocal laser-scanning microscope 
(Zeiss, Oberkochen, Germany). TUNEL assay analysis was performed using Image J software.
DNA manipulations. Plasmid DNA from E. coli was prepared using a DNA Spin Plasmid DNA purifica-
tion Kit (Intron Biotechnology, Korea) or a NucleoBondTM Xtra Maxi Plus EF kit (Macherey-Nagel, Germany). 
General genetic engineering experiments were performed as described by Sambrook and Russell37.
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